There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin Pharmaceutical (BMRN – Research Report) and Sanofi (SNYNF – Research Report) with bullish sentiments.
BioMarin Pharmaceutical (BMRN)
In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on BioMarin Pharmaceutical, with a price target of $147.00. The company’s shares closed last Wednesday at $80.31.
According to TipRanks.com, Moussatos has 0 stars on 0-5 stars ranking scale with an average return of
BioMarin Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $112.75, implying a 41.0% upside from current levels. In a report issued on April 25, Morgan Stanley also upgraded the stock to Buy with a $113.00 price target.
Goldman Sachs analyst Keyur Parekh maintained a Buy rating on Sanofi today and set a price target of EUR127.00. The company’s shares closed last Tuesday at $107.69.
Parekh has an average return of
According to TipRanks.com, Parekh is ranked #1591 out of 7888 analysts.
Sanofi has an analyst consensus of Moderate Buy, with a price target consensus of $118.58, representing an 8.7% upside. In a report issued on April 18, Jefferies also maintained a Buy rating on the stock with a EUR135.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BMRN: